Navigation Links
Skyline Diagnostics and Clavis Pharma to Collaborate on Patient Selection Biomarker Discovery for Leukemia Drug elacytarabine
Date:9/6/2011

ROTTERDAM, The Netherlands, September 6, 2011 /PRNewswire/ --

The Dutch biotech company Skyline Diagnostics B.V. (Skyline) and the Norwegian drug development company Clavis Pharma ASA (Clavis) disclosed signing a research agreement. Under this agreement, Skyline will investigate gene expression biomarkers for selection of individual Acute Myeloid Leukemia (AML) patients that may benefit from a new AML drug in development at Clavis. This drug, elacytarabine, is a novel elaidic acid derivative of cytarabine and currently undergoing the CLAVELA phase III study for treatment of patients with relapsed/refractory AML.

"For Clavis and for elacytarabine this is an important collaboration. Skyline Diagnostics's expertise will be instrumental in searching for gene expression patterns that can be utilized in the further biomarker program of elacytarabine," said Athos Gianella-Borradori, CMO of Clavis Pharma, "this genomic approach adds to our currently ongoing patient selection based on  protein markers and will deepen our insights into the potential for precise and highly effective personalized medicines. It is our goal and vision that this collaboration with the experts of Skyline will bring better therapies to the many patients suffering from difficult-to-treat leukemia."

"After the successful launch of the AMLprofiler in Europe, we are pleased to further strengthen our companion diagnostics activities," said Henk Viëtor, CEO of Skyline.

"Pharma companies are recognizing the value of companion diagnostics in positioning their drugs. By applying our bioinformatics engine, product development and regulatory experience, we can add substantial value to the process of drug development. We look forward working together with Clavis Pharma on this exciting personalized medicine opportunity."

About Skyline Diagnostics B.V.

Skyline Diagnostics develops and markets array-based diagnostic tests for personalized medicine. Skyline's product the AMLprofiler simplifies AML diagnostics by replacing 7 separate assays by a single microarray-based test. The company has built strong collaborations with leading scientists and pharmaceutical companies and has several strategic alliances with industrial partners for distribution and manufacturing.

About Clavis Pharma ASA

Clavis Pharma ASA is a late clinical stage oncology discovery and drug development company with a portfolio of novel anti-cancer drugs in development. These patented New Chemical Entities (NCEs) are novel, improved versions of commercially successful drugs, made using Clavis Pharma's Lipid Vector Technology (LVT) chemistry. Data generated suggests these potential breakthrough products may offer improved efficacy and reduced side effects.

http://www.skyline-diagnostics.com

http://www.clavispharma.com


'/>"/>
SOURCE Skyline Diagnostics B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SI-BONE, Inc. Closes $11.0 Million Financing Led by Skyline Ventures
2. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
3. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
6. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
7. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
10. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
11. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Story Highlights: , ... health care industry is causing providers to review operating ... offers a suite of solutions for health care providers ... optimization: labor resource analysis, revenue cycle optimization and physician ... and better economics ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
Breaking Medicine News(10 mins):